Pages that link to "Q54347600"

The following pages link to A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. (Q54347600):

Displaying 43 items.

• Biomarkers to guide clinical therapeutics in rheumatology? (Q28080053) ‎ (← links)
• Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial (Q30807010) ‎ (← links)
• B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. (Q33616360) ‎ (← links)
• De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. (Q34112037) ‎ (← links)
• Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations (Q34419596) ‎ (← links)
• Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. (Q35077861) ‎ (← links)
• Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response (Q35654669) ‎ (← links)
• Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis (Q35759180) ‎ (← links)
• Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations. (Q36860748) ‎ (← links)
• Mechanistic biomarkers for clinical decision making in rheumatic diseases (Q36905584) ‎ (← links)
• Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study (Q36975931) ‎ (← links)
• A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study (Q37203531) ‎ (← links)
• Rituximab for the treatment of rheumatoid arthritis: an update (Q37444678) ‎ (← links)
• PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis (Q37690298) ‎ (← links)
• B-cell targeted therapeutics in clinical development (Q38097162) ‎ (← links)
• Rituximab biosimilars (Q38100232) ‎ (← links)
• Impact of rituximab trials on the treatment of ANCA-associated vasculitis (Q38152651) ‎ (← links)
• Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine (Q38218692) ‎ (← links)
• Sequencing the functional antibody repertoire--diagnostic and therapeutic discovery (Q38299138) ‎ (← links)
• Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. (Q38690022) ‎ (← links)
• Editorial: IgA Responses and Future Development of Rheumatoid Arthritis (Q38849918) ‎ (← links)
• Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics (Q38988559) ‎ (← links)
• Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors (Q39160831) ‎ (← links)
• Optimization of current and future therapy for autoimmune diseases (Q39666645) ‎ (← links)
• The quest for personalized B-cell depletion therapy in rheumatic disease (Q41482035) ‎ (← links)
• Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis (Q41846224) ‎ (← links)
• Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? (Q42633541) ‎ (← links)
• Barcode-enabled sequencing of plasmablast antibody repertoires in rheumatoid arthritis. (Q42668546) ‎ (← links)
• High-throughput characterization of the functional impact of IgG Fc glycan aberrancy in juvenile idiopathic arthritis. (Q45945255) ‎ (← links)
• Autoantibodies From Single Circulating Plasmablasts React With Citrullinated Antigens and Porphyromonas gingivalis in Rheumatoid Arthritis. (Q48072438) ‎ (← links)
• NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. (Q48250996) ‎ (← links)
• A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. (Q48347863) ‎ (← links)
• Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. (Q50910869) ‎ (← links)
• Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al. (Q52839527) ‎ (← links)
• An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. (Q52840446) ‎ (← links)
• [Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy]. (Q52885796) ‎ (← links)
• Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. (Q55027964) ‎ (← links)
• Tweaking the B lymphocyte compartment in autoimmune diseases (Q58003021) ‎ (← links)
• Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis (Q64280249) ‎ (← links)
• Antibody repertoire analysis in polygenic autoimmune diseases (Q88161098) ‎ (← links)
• The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases (Q88576833) ‎ (← links)
• Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial (Q88974741) ‎ (← links)
• Definition of erythroid cell-positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection (Q104617817) ‎ (← links)